-
1
-
-
0000600880
-
Familial hypercholesterolemia
-
Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B, eds 8th ed. New York, NY: McGraw-Hill
-
Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Sly WS, Childs B, Beaudet AL, Valle D, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2863-2913.
-
(2001)
The Metabolic and Molecular Bases of Inherited Disease
, pp. 2863-2913
-
-
Goldstein, J.L.1
Hobbs, H.H.2
Brown, M.S.3
-
2
-
-
44849108492
-
Update and analysis of the university college London low density lipoprotein receptor familial hypercholesterolemia database
-
DOI 10.1111/j.1469-1809.2008.00436.x
-
Leigh SE, Foster AH, Whittall RA, Hubbart CS, Humphries SE. Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database. Ann Hum Genet. 2008; 72:485-498. (Pubitemid 351850090)
-
(2008)
Annals of Human Genetics
, vol.72
, Issue.4
, pp. 485-498
-
-
Leigh, S.E.A.1
Foster, A.H.2
Whittall, R.A.3
Hubbart, C.S.4
Humphries, S.E.5
-
3
-
-
0016373413
-
Coronary artery disease in 116 kindred with familial type II hyperproteinemia
-
Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperproteinemia. Circulation. 1974; 49:476-488.
-
(1974)
Circulation
, vol.49
, pp. 476-488
-
-
Stone, N.J.1
Levy, R.I.2
Fredrickson, D.S.3
Verter, J.4
-
4
-
-
34548384234
-
Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia
-
DOI 10.1016/j.jacl.2007.07.003, PII S1933287407001948
-
Stein EA, Ose L, Retterstøl K, Tonstad S, Schleman M, Harris S, Sager P. Further reduction of low-density lipoprotein cholesterol and C-reactive protein with the addition of ezetimibe to maximum-dose rosuvastatin in patients with severe hypercholesterolemia. J Clin Lipidol. 2007;1: 280-286. (Pubitemid 47364514)
-
(2007)
Journal of Clinical Lipidology
, vol.1
, Issue.4
, pp. 280-286
-
-
Stein, E.A.1
Ose, L.2
Retterstol, K.3
Tonstad, S.4
Schleman, M.5
Harris, S.6
Sager, P.7
-
5
-
-
4644256971
-
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: Efficacy and safety of ezetimibe co-administered with atorvastatin
-
DOI 10.1016/j.ahj.2004.03.052, PII S0002870304002674
-
Stein E, Stender S, Mata P, Sager P, Ponsonnet D, Melani L, Lipka L, Suresh R, MacCubbin D, Veltri E; Ezetimibe Study Group. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J. 2004;148:447-455. (Pubitemid 39265117)
-
(2004)
American Heart Journal
, vol.148
, Issue.3
, pp. 447-455
-
-
Stein, E.1
Stender, S.2
Mata, P.3
Sager, P.4
Ponsonnet, D.5
Melani, L.6
Lipka, L.7
Suresh, R.8
MacCubbin, D.9
Veltri, E.10
-
6
-
-
77049105368
-
Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large crosssectional study in the Netherlands
-
Pijlman AH, Huijgen R, Verhagen SN, Imholz B, Liem A, Kastelein J, Abbink E, Stalenhoef, Visseren F. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large crosssectional study in the Netherlands. Atherosclerosis. 2010;209:189-194.
-
(2010)
Atherosclerosis
, vol.209
, pp. 189-194
-
-
Pijlman, A.H.1
Huijgen, R.2
Verhagen, S.N.3
Imholz, B.4
Liem, A.5
Kastelein, J.6
Abbink, E.7
Stalenhoef8
Visseren, F.9
-
7
-
-
44149123549
-
Recommendations for the use of LDL apheresis
-
HEART-UK LDL Apheresis Working Group
-
Thompson GR; HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198: 247-255.
-
(2008)
Atherosclerosis
, vol.198
, pp. 247-255
-
-
Thompson, G.R.1
-
8
-
-
77149160366
-
Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia
-
Thomas T, Ginsberg H. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia. Curr Atheroscler Rep. 2010; 12:58-65.
-
(2010)
Curr Atheroscler Rep
, vol.12
, pp. 58-65
-
-
Thomas, T.1
Ginsberg, H.2
-
9
-
-
33750207033
-
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
-
DOI 10.1161/CIRCULATIONAHA.105.606442, PII 0000301720061017000012
-
Kastelein JJ, Wedel MK, Baker BF, Su J, Bradley J, Yu R, Chuang E, Graham M, Crooke R. Potent reduction of apolipoprotein B and lowdensity lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation. 2006;114: 1729-1735. (Pubitemid 44607121)
-
(2006)
Circulation
, vol.114
, Issue.16
, pp. 1729-1735
-
-
Kastelein, J.J.P.1
Wedel, M.K.2
Baker, B.F.3
Su, J.4
Bradley, J.D.5
Yu, R.Z.6
Chuang, E.7
Graham, M.J.8
Crooke, R.M.9
-
10
-
-
77949485460
-
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: A randomised, double-blind, placebocontrolled trial
-
Raal FJ, Santos RD, Blom DJ, Marais A, Charng M, Cromwell W, Lashmann R, Gaudet D, Tan J, Chasan-Taber S, Tribble D, Flaim J, Crooke S. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebocontrolled trial. Lancet. 2010;375:998-1006.
-
(2010)
Lancet
, vol.375
, pp. 998-1006
-
-
Raal, F.J.1
Santos, R.D.2
Blom, D.J.3
Marais, A.4
Charng, M.5
Cromwell, W.6
Lashmann, R.7
Gaudet, D.8
Tan, J.9
Chasan-Taber, S.10
Tribble, D.11
Flaim, J.12
Crooke, S.13
-
11
-
-
77950332314
-
Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy
-
Akdim F, Stroes ES, Sijbrands EJ, Tribble D, Trip M, Jukema J, Flaim J, Su J, Yu R, Baker B, Wedel M, Kastelein J. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol. 2010;55:1611-1618.
-
(2010)
J Am Coll Cardiol
, vol.55
, pp. 1611-1618
-
-
Akdim, F.1
Stroes, E.S.2
Sijbrands, E.J.3
Tribble, D.4
Trip, M.5
Jukema, J.6
Flaim, J.7
Su, J.8
Yu, R.9
Baker, B.10
Wedel, M.11
Kastelein, J.12
-
12
-
-
77951069859
-
Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia
-
Akdim F, Visser ME, Tribble DL, Baker B, Stroes E, Yu R, Flaim J, Su J, Stein E, Kastelein J. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol. 2010;105:1413-1419.
-
(2010)
Am J Cardiol
, vol.105
, pp. 1413-1419
-
-
Akdim, F.1
Visser, M.E.2
Tribble, D.L.3
Baker, B.4
Stroes, E.5
Yu, R.6
Flaim, J.7
Su, J.8
Stein, E.9
Kastelein, J.10
-
13
-
-
0025944056
-
Risk of fatal coronary heart disease in familial hypercholesterolaemia
-
Scientific Steering Committee on behalf of the Simon Broome Register Group
-
Scientific Steering Committee on behalf of the Simon Broome Register Group. Risk of fatal coronary heart disease in familial hypercholesterolaemia. BMJ. 1991;303:893-896.
-
(1991)
BMJ
, vol.303
, pp. 893-896
-
-
-
14
-
-
0037126526
-
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III final report
-
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143-3421.
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
-
15
-
-
64949095273
-
Nonalcoholic fatty liver disease: Diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5T
-
Yokoo T, Bydder M, Hamilton G, Middleton M, Gamst A, Wolfson T, Hassanein T, Patton H, Lavine J, Schwimmer J, Sirlin C. Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5T. Radiology. 2009; 251:67-76.
-
(2009)
Radiology
, vol.251
, pp. 67-76
-
-
Yokoo, T.1
Bydder, M.2
Hamilton, G.3
Middleton, M.4
Gamst, A.5
Wolfson, T.6
Hassanein, T.7
Patton, H.8
Lavine, J.9
Schwimmer, J.10
Sirlin, C.11
-
16
-
-
0036827347
-
The college of American Pathologists laboratory accreditation program
-
DOI 10.1007/s00769-002-0537-0
-
Rabinovitch A. The College of American Pathologists laboratory accreditation program. Accred Qual Assur. 2002:7;473-476. (Pubitemid 36165310)
-
(2002)
Accreditation and Quality Assurance
, vol.7
, Issue.11
, pp. 473-476
-
-
Rabinovitch, A.1
-
17
-
-
0024549783
-
The Centers for Disease Control-National Heart, Lung and Blood Institute lipid standardization program. An approach to accurate and precise lipid measurements
-
Myers GL, Cooper GR, Winn CL, Smith SJ. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin Lab Med. 1989;9:105-135. (Pubitemid 19070302)
-
(1989)
Clinics in Laboratory Medicine
, vol.9
, Issue.1
, pp. 105-135
-
-
Myers, G.L.1
Cooper, G.R.2
Winn, C.L.3
Smith, S.J.4
-
18
-
-
0020004724
-
Dextran sulfate-Mg2-precipitation procedure for quantitation of high-density-lipoprotein cholesterol
-
Warnick GR, Benderson J, Albers JJ. Dextran sulfate-Mg2-precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Selected Methods Clin Clem. 1982:28;1379-1388.
-
(1982)
Selected Methods Clin Clem
, vol.28
, pp. 1379-1388
-
-
Warnick, G.R.1
Benderson, J.2
Albers, J.J.3
-
19
-
-
0028179990
-
International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B IV: Comparability of apolipoprotein B values by use of international reference material
-
Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B, IV: comparability of apolipoprotein B values by use of international reference material. Clin Chem. 1994;40:586-592.
-
(1994)
Clin Chem
, vol.40
, pp. 586-592
-
-
Marcovina, S.M.1
Albers, J.J.2
Kennedy, H.3
Mei, J.V.4
Henderson, L.O.5
Hannon, W.H.6
-
20
-
-
33744506277
-
Drug-induced liver injury: Hy's rule revisited
-
DOI 10.1016/j.clpt.2006.02.012, PII S0009923606000841
-
Björnsson E. Drug-induced liver injury: Hy's rule revisited. Clin Pharmacol Ther. 2006;79:521-528. (Pubitemid 43817945)
-
(2006)
Clinical Pharmacology and Therapeutics
, vol.79
, Issue.6
, pp. 521-528
-
-
Bjornsson, E.1
-
22
-
-
35348903316
-
Long-Term Efficacy and Safety of Rosuvastatin 40 mg in Patients With Severe Hypercholesterolemia
-
DOI 10.1016/j.amjcard.2007.06.029, PII S0002914907014324
-
Stein EA, Amerena J, Ballantyne CM, Brice E, Farnier M, Guthrie RM, Harats D, Ma P, Le Maulf F, Melezinkova H, Gold A, Sager P. Long-term efficacy and safety of rosuvastatin 40 mg in patients with severe hypercholesterolemia. Am J Cardiol. 2007;100:1387-1396. (Pubitemid 47576017)
-
(2007)
American Journal of Cardiology
, vol.100
, Issue.9
, pp. 1387-1396
-
-
Stein, E.A.1
Amerena, J.2
Ballantyne, C.M.3
Brice, E.4
Farnier, M.5
Guthrie, R.M.6
Harats, D.7
Ma, P.8
Le Maulf, F.9
Melezinkova, H.10
Gold, A.11
Sager, P.12
-
23
-
-
33645096052
-
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: Report of the thirty-person/ten-country panel
-
Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, De Graaf J, Durrington P, Faergeman O, Frohlich J, Furberg CD, Gagne C, Haffner SM, Humphries SE, Junger I, Krauss RM, Kwiterovich P, Marcovinia S, Packard CJ, Pearson TA, Srinath Reddy K, Rosenson R, Sarrafzadegan N, Sniderman AD, Stalenhoef AF, Stein E, Talmud PJ, Tonkin AM, Walldius G, Williams KMS. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259: 247-258.
-
(2006)
J Intern Med
, vol.259
, pp. 247-258
-
-
Barter, P.J.1
Ballantyne, C.M.2
Carmena, R.3
Castro Cabezas, M.4
Chapman, M.J.5
Couture, P.6
De Graaf, J.7
Durrington, P.8
Faergeman, O.9
Frohlich, J.10
Furberg, C.D.11
Gagne, C.12
Haffner, S.M.13
Humphries, S.E.14
Junger, I.15
Krauss, R.M.16
Kwiterovich, P.17
Marcovinia, S.18
Packard, C.J.19
Pearson, T.A.20
Srinath Reddy, K.21
Rosenson, R.22
Sarrafzadegan, N.23
Sniderman, A.D.24
Stalenhoef, A.F.25
Stein, E.26
Talmud, P.J.27
Tonkin, A.M.28
Walldius, G.29
Williams, K.M.S.30
more..
-
24
-
-
0037069339
-
Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy
-
DOI 10.1161/01.CIR.0000038419.53000.D6
-
Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation. 2002; 106:2526-2529. (Pubitemid 35340685)
-
(2002)
Circulation
, vol.106
, Issue.20
, pp. 2526-2529
-
-
Grundy, S.M.1
-
25
-
-
70350360003
-
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations
-
Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis G, Grover S, Gupta M, Hegele R, Lau D, Leiter L, Lewis G, Lonn E, Mancini F, Ng D, Pearson G, Sniderman A, Stone J, Ur E. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations. Can J Cardiol. 2009;25:567-579.
-
(2009)
Can J Cardiol
, vol.25
, pp. 567-579
-
-
Genest, J.1
McPherson, R.2
Frohlich, J.3
Anderson, T.4
Campbell, N.5
Carpentier, A.6
Couture, P.7
Dufour, R.8
Fodor, G.9
Francis, G.10
Grover, S.11
Gupta, M.12
Hegele, R.13
Lau, D.14
Leiter, L.15
Lewis, G.16
Lonn, E.17
Mancini, F.18
Ng, D.19
Pearson, G.20
Sniderman, A.21
Stone, J.22
Ur, E.23
more..
-
26
-
-
39649084902
-
A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia
-
DOI 10.1016/j.atherosclerosis.2007.06.028, PII S0021915007004005
-
Marais AD, Raal FJ, Stein EA, Rader D, Blasetto J, Palmer M, Wilpshaar W. A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis. 2008;197:400-406. (Pubitemid 351284477)
-
(2008)
Atherosclerosis
, vol.197
, Issue.1
, pp. 400-406
-
-
Marais, A.D.1
Raal, F.J.2
Stein, E.A.3
Rader, D.J.4
Blasetto, J.5
Palmer, M.6
Wilpshaar, W.7
-
27
-
-
78649888517
-
European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status
-
Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts G, Ginsberg H, Amarenco P, Catapano A, Descamps O, Fisher E, Kovanen P, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, Tyberg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844-2853.
-
(2010)
Eur Heart J
, vol.31
, pp. 2844-2853
-
-
Nordestgaard, B.G.1
Chapman, M.J.2
Ray, K.3
Boren, J.4
Andreotti, F.5
Watts, G.6
Ginsberg, H.7
Amarenco, P.8
Catapano, A.9
Descamps, O.10
Fisher, E.11
Kovanen, P.12
Kuivenhoven, J.A.13
Lesnik, P.14
Masana, L.15
Reiner, Z.16
Taskinen, M.R.17
Tokgozoglu, L.18
Tyberg-Hansen, A.19
-
28
-
-
0025365313
-
Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia
-
Seed M, Hoppichler F, Reaveley D, McCarthy S, Thompson G, Boerwinkle E, Utermann G. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N Engl J Med. 1990;322:1494-1499. (Pubitemid 20179863)
-
(1990)
New England Journal of Medicine
, vol.322
, Issue.21
, pp. 1494-1499
-
-
Seed, M.1
Hoppichler, F.2
Reaveley, D.3
McCarthy, S.4
Thompson, G.R.5
Boerwinkle, E.6
Utermann, G.7
-
29
-
-
48349088178
-
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
-
Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497-505.
-
(2008)
Nat Clin Pract Cardiovasc Med
, vol.5
, pp. 497-505
-
-
Samaha, F.F.1
McKenney, J.2
Bloedon, L.T.3
Sasiela, W.J.4
Rader, D.J.5
-
30
-
-
33645889332
-
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
-
National Lipid Association Statin Safety Assessment Task Force
-
McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97:89C-94C.
-
(2006)
Am J Cardiol
, vol.97
-
-
McKenney, J.M.1
Davidson, M.H.2
Jacobson, T.A.3
Guyton, J.R.4
-
31
-
-
0343204478
-
-
Morris Plains NJ: Parke-Davis Division of Warner-Lambert Co
-
Lipitor [package insert]. Morris Plains, NJ: Parke-Davis Division of Warner-Lambert Co; 1997.
-
(1997)
Lipitor [Package Insert]
-
-
-
32
-
-
11244296431
-
A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial
-
DOI 10.1185/03007990152005351
-
Illingworth DR, Crouse JR III, Hunninghake DB, Davidson MH, Escobar ID, Stalenhoef AF, Paragh G, MA PT, Liu M, Melino MR, O'grady L, Mercuri M, Mitchel YB; Simvastatin Atorvastatin HDL Study Group. A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial. Curr Med Res Opin. 2001;17:43-50. (Pubitemid 32594972)
-
(2001)
Current Medical Research and Opinion
, vol.17
, Issue.1
, pp. 43-50
-
-
Illingworth, D.R.1
Crouse III, J.R.2
Hunninghake, D.B.3
Davidson, M.H.4
Escobar, I.D.5
Stalenhoef, A.F.H.6
Paragh, G.7
Ma, P.T.8
Liu, M.9
Melino, M.R.10
O'Grady, L.11
Mercuri, M.12
Mitchel, Y.B.13
-
33
-
-
84895538483
-
Effects of low dose MTP inhibition alone and in combination with other lipid-lowering drugs on hepatic fat and plasma lipids
-
Abstract 103
-
Meagher E, Davidson M, Rosen M, Robinson J, Bays H, Bloedon L, Sasiela W, Parris M, Rader D. Effects of low dose MTP inhibition alone and in combination with other lipid-lowering drugs on hepatic fat and plasma lipids. Abstracts of the XV International Symposium on Atherosclerosis. Atheroscler Suppl. 2009;10:e228. Abstract 103.
-
(2009)
Abstracts of the XV International Symposium on Atherosclerosis. Atheroscler Suppl
, vol.10
-
-
Meagher, E.1
Davidson, M.2
Rosen, M.3
Robinson, J.4
Bays, H.5
Bloedon, L.6
Sasiela, W.7
Parris, M.8
Rader, D.9
|